12 questions to ask before booking a cell-related intervention abroad
These 12 questions organise product, evidence, regulation, safety, cost and follow-up checks. Answers still require verification with official sources and independent clinicians.
1. What is the exact product or preparation? 2. What diagnosis, stage and patient population is it proposed for? Record source, donor relationship, manipulation, dose, route, schedule, manufacturer and site rather than accepting a broad therapy name.
3. What is the exact legal pathway and reference? 4. Which authority can confirm it? Distinguish marketing authorisation, authorised clinical trial and specific national exemption from facility licensing, ethics review, GMP certification or registry listing.
5. What human evidence matches this product and indication? 6. What are the prespecified benefits, time points and uncertainties? 7. What adverse events, withdrawals and missing outcomes were reported? Ask for complete studies rather than testimonials or selected responder percentages.
8. What established alternatives have been considered? 9. Who determines eligibility and manages complications? 10. What written follow-up and emergency plan applies after return? Obtain independent specialist advice and do not assume a home clinician has accepted responsibility.
11. What does the dated quotation include and exclude? 12. What happens after ineligibility, failed collection or batch release, postponement, cancellation or additional care? Preserve source currency and add travel separately. Use the ISSCR patient guide and EMA/HMA warning to verify the answers.
Sources & further reading
- Stem-cell trials registry (ClinicalTrials.gov) ↗
- Peer-reviewed research (PubMed) ↗
- ISSCR — patient resources ↗
- FDA — consumer guidance ↗
- EMA — ATMP framework ↗
Commercial price observations are heterogeneous and most cell-therapy uses remain investigational. Verify source scope, regulatory status and the proposed care with an independent qualified physician.